D-0008-2022 Class I Terminated

Recalled by Jacobus Pharmaceutical Company Inc. — Plainsboro, NJ

FDA drug recall D-0008-2022 was initiated by Jacobus Pharmaceutical Company Inc. on Sep 9, 2021 and is designated Class I. Reason for recall: Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts. The recall status is terminated (terminated Feb 18, 2022). Affected quantity: 2,324 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 6, 2021
Initiation Date
Sep 9, 2021
Termination Date
Feb 18, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,324 bottles

Product description

Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.

Reason for recall

Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.

Distribution pattern

Product was distributed within the USA and Canada. Control # 18038, was distributed to Canada only.

Code information

Lot #: 18038, 18039, Exp 03/2023; 18079, Exp 05/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0008-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0008-2022. Report a data issue: hello@regdatalab.com.